The FDA has approved Botox for the treatment of lower limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. The treatment was already approved for pediatric upper limb spasticity earlier this year.
Compared with placebo, high dose aducanumab was associated with significant reduction of clinical decline in patients with early Alzheimer disease, as measured by the change from baseline in Clinical Dementia Rating-Sum of Boxes score at 78 weeks.
The FDA has approved Reyvow for the acute treatment of migraine with or without aura in adults.
Results showed that when co-administered with Tdap, the vaccine response rate to RZV was 97.8%.
